Efficacy and tolerability of ferrous sulphate vs iron peptone + ferrous ascorbate in pregnancy: An observational study
Efficacy and tolerability of ferrous sulphate vs iron peptone + ferrous ascorbate in pregnancy
Keywords:
Iron deficiency anemia, Efficacy, Iron supplements, TolerabilityAbstract
Introduction: Iron stores in pregnancy are essential in preventing negative outcomes for both infant and mother. The association of iron deficiency anemia (IDA) in pregnancy is high in spite of iron supplementation being in regular practice. The main signs and symptoms of IDA are fatigue, breathlessness, weakness, pallor and rapid heartbeat and the treatment to this is giving iron supplements. Intolerability of oral iron preparations results in decreased compliance. Tolerability is influenced by several factors – age, body mass, socioeconomic status (genetic variants). Aims/Objectives : To compare the efficacy and tolerability of two iron preparations (oral); Iron Peptone + Ferrous Ascorbate (IP+FA) Vs Ferrous Sulphate in the treatment of IDA during pregnancy Material and Methods: A prospective, observational, cross sectional study was conducted at the Department of Obstetrics and Gynecology, V.S. Hospital Ahmedabad, a tertiary care teaching hospital. Second and third trimester pregnant females diagnosed with anemia (Hb< 11gm/dl) were included in the study. Patients who were not willing to give informed consent were excluded from the study. Results: We collected data of 59 Patients diagnosed with anemia (Hb between 7-10.9 gm/dl) , 35 women received ferrous sulfate and 23 were given IP+FA and both groups were followed up after 30 days. There was significant increase in hemoglobin in both the groups. The change in hemoglobin (Hb) of women receiving ferrous sulfate was 9.129±1.098 gm/dl with p value of 0.701 and those receiving IP+FA was 9.490±1.909 gm/dl with p value of 0.102. There was no significant difference in efficacy between the two treatment groups. Most common adverse drug reaction (ADR) during therapy were nausea (31.9%) , followed by constipation (27.6%) and heart burn (25.5%) patients. Other ADRs like metallic taste, vomiting, headache and epigastric pain were less common. IP+FA had more adverse drug reactions than patients receiving ferrous sulfate. Conclusion: The efficacy of both iron preparations was found to be similar with patients receiving IP+FA having greater number of ADRs
References
2. Milman N, Paszkowski T, Cetin I, Castelo-Branco C. Supplementation during pregnancy: beliefs and science. Gynecol Endocrinol 2016;32:7.
3. Pavan PJ, Mira Dk. Comparison of Efficacy, Safety and Cost of Therapy with Oral Ferrous Ascorbate and Ferrous Sulphate in Patients with Iron Deficiency Anemia. Drug Discov Ther 2014;2:20:47-53.
4. Genes Nutr 2015;10:4:272.
5. Adamson JW. Iron Deficiency and Other Hypoproliferative Anemias. Harrison’s Principles of Internal Medicine. 18th EdMcGraw Hill Delhi 2011;586-93.
6. D Arora Bhoomi. A Comparative Study of use of Preparation Containing Ferrous sulphate versus Ferrousfumarate in Treatment of Iron Deficiency Anemia. Int J Pharm Biol Sci Arch 2010;1:5:429-35.
7. Afzal M, Qureshi S M, Lutafullah M, Iqbal M, Sultan M, Khan S A. Comparative study of efficacy, tolerability and compliance of oral iron preparations and intramuscular Iron sorbitol in iron deficiency anemia in children. J Pak Med Assoc 2009;59:11:764-68.
8. Joseph T. DiPiro, Robert L. Talbert, Gary C. Yee, Gary R. Matzke, Barbara G. Wells, L. Michael Posey. Hematologic Disorders-Anemia. Pharmacotherapy: A Pathophysiologic Approach. 8th ed. USA: McGraw Hill. 2011:1023-47.
9. Masters SB. Agents Used in Anemia; hematopoietic Growth Factors.In: Katzung BG`s Basic & Clinical Pharmacology. 12th ed. McGraw Hill Lange. 2013:581-659.
10. United Nations Children’s Fund/World Health Organization. Prevention and control of iron deficiency anaemia in women and children. Geneva, Switzerland: UNICEF/WHO; 1999.
11. Hyder SM, Persson LA, Chowdhury AM, Ekström EC. Do side-effects reduce compliance to iron supplementation? A study of daily- and weekly-dose regimens in pregnancy. J Health Popul Nutr 2002; 20:175–179.
12. Barut A, Harma M. Intravenous iron treatment for iron deficiency anaemia in pregnancy. J Turkish-German Gynecol Assoc 2009;10:109–15.
13. Sharma N. Iron absorption: IPC therapy is superior to conventional iron salts. Obstet Gynecol 2001:515–19.
14. Jeremy H Brock. Biochem Cell Biol 2012;90:3:245-51.
15. Iron and folate supplementation: integrated management of pregnancy and childbirth. Standards for maternal and neonatal Geneva: Department of Making Pregnancy Safer, World Health Organization; 2006
16. Mimura EC, Breganó JW, Dichi JB, Gregório EP, Dichi I. J Perinat Med 2014;42:2:197-206.
17. Bhargava Richa ,MaheshwariM.Comparative Study of Intravenous iron Sucrose and Oral Iron in Iron Deficiency Anaemia among Pregnant Women in Rural. J Evolution Med Dent Sci 2013;2:16:2750-55.
18. Patkar VD, Patkar S, Khandeparker PS, Dingankar NS, Shetty RS. Evaluation of efficacy and tolerability of iron
(III) – hydroxide polymaltose complex tablets in the treatment of iron deficiency anaemia in women. Indian Med Gazette 2001;135:306–09.
19. Singhal et al. Comparison of Various Oral Iron Salts in the Treatment of Iron Deficiency Anemia. Indian J Obstet Gyn Res 2015;2:3:155-58.
20. Kamdi SP, Palkar PJ. Efficacy and safety of ferrous aspartoglycinate in the management of iron deficiency anaemia in pregnant women. J Obstet Gynaecol 2015;35(1):4-8.
21. Casparis D, Del Carlo P, Branconi F, Grossi A, Merante D, GafforioL..Effectiveness and tolerability of oral liquid ferrous gluconate in iron-deficiency anemia in pregnancy and in the immediate post-partum period: comparison with other liquid or solid formulations containing bivalent or trivalent iron. Minerva Ginecol1996;48(11):511-811.
22. Comparison of Efficacy and Safety Profile of Oral Iron Formulations in Patients with Iron Deficiency Anemia. Int J Pharm Sci Rev 2016;41(2):248-52
